Relation between the Genetic Variants of SLC47A1 (MATE1) and the Response to Metformin Therapy in Iraqi Women with Polycystic Ovarian Syndrome


Background: Metformin is widely used in polycystic ovary syndrome (PCOS), nevertheless, the treatment responsiveness reveals individual variation in patients with PCOS. Multidrug and toxins extrusion protein (MATE1) mediates metformin excretion in kidney and bile. MATE1 is encoded by SLC47A1 gene. In this study the single-nucleotide polymorphism (SNP) (rs1961669 A>G) was analyzed in an attempt to investigate the clinical, hormonal and biochemical effects of three months metformin treatment in women with polycystic ovary syndrome and to study the relation between MATE1 (SLC47A1) gene polymorphism and the response to metformin. Patients and Methods: This study is a prospective group study; 231 women with PCOS were enrolled. All participated women with age range (18-40) were starting metformin tablet 500 mg per oral three times daily. Blood samples were taken from eligible patients to perform genetic analysis and estimation of follicle stimulating hormone, luteinizing hormone, total testosterone, fasting insulin, HbA1c, fasting blood glucose, sex hormone binding globulin and lipid profile. Results: The study showed that SLC47A1 (rs1961669) (A>G) gene polymorphism has non-significant association with metformin response in PCOS. The comparison in demographic and biochemical parameters between pre and post metformin treatment results showed no improvement in clinical, hormonal and biochemical parameters. Conclusion: SLC47A1 (rs1961669) (A>G) gene polymorphism had no association with clinical, hormonal and biochemical response to metformin in Iraqi women with polycystic ovarian syndrome.